LUND, Sweden – Cellevate AB, an innovative biotech company developing the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces a poster presentation at the Advanced Therapies congress in London on March 19-20, 2024. In the poster, we present positive results on the use of the 1st nanofiber-based microcarriers, Cellevat3dTM microcarriers, in upstream bioprocessing of viral vector production.
The details of the poster presentation are as follows:
Title: Cellevat3dTM nanofiber-based microcarriers designed for improved upstream productivity of viral vector biomanufacturing
Presenter: Linda Dexlin Mellby, PhD, VP R&D Cellevate
Session Date & Time: March 20, 2024 at 10:30-11:00 am.
Location: ExCeL, London
For more information please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center, at Lund University in Sweden. The company develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber materials – “microcarriers” – with unparalleled surface area for cell growth, reproducibility and customization, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d™ microcarriers products are designed as an integrated part of upstream bioprocess solutions, starting with laboratory testing of cell lines followed by pilot and large-scale batch production of gene therapies. Cellevat3d™ microcarriers launch is planned for 2024.
For more information, please visit www.cellevate.com.
